<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516590</url>
  </required_header>
  <id_info>
    <org_study_id>XijingH Deng Yanchun-1</org_study_id>
    <nct_id>NCT04516590</nct_id>
  </id_info>
  <brief_title>The Diagnostic Value of Autoimmune Antibody Detection in Newly Onset and Chronic Epilepsy</brief_title>
  <official_title>The Diagnostic Value of Autoimmune Antibody Detection in Newly Onset and Chronic Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Hospital of Ningxia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wulumuqi General Hospital of Lanzhou Military Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Qinghai University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      multi-central and prospectively study the diagnostic value of autoimmune antibody detection&#xD;
      in new and chronic epilepsy, and provide reference for clinical practice&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      multi-centrally recruit patients with newly onset or chronic epilepsy and hoping to find&#xD;
      whether there exist an autoimmune cause. whether the patients receive immune therapy or not&#xD;
      will depend on the type and titter of the autoimmune antibody as well as the severity of the&#xD;
      symptom. At 3 and 6 months later, all patients will be followed-up, and the positive&#xD;
      autoimmune antibody will be redetected. the clinical manifest, clinical data, medication and&#xD;
      treatment outcome will be recorded and analyzed, to study the diagnostic value of autoimmune&#xD;
      antibody detection in new and chronic epilepsy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change of the seizure frequency</measure>
    <time_frame>at six months after the patients being enrolled</time_frame>
    <description>Seizure frequency are described as no seizures, less than one per month, monthly, weekly, and daily. the change of seizure frequency include 'increased', 'decreased', and 'no change' compared to the frequency before they were enrolled</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change of the autoimmune antigen</measure>
    <time_frame>at six months after the patients being enrolled</time_frame>
    <description>autoimmune antigen in the serum of patients was described as positive and negative. the change of the autoimmune antigen include 'turn negative' and 'still positive' compared to the first detection.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>autoimmune antigen negative</arm_group_label>
    <description>treated with anti-epilepsy drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>autoimmune antigen positive</arm_group_label>
    <description>whether the patients receive immune therapy or not will depend on the type and titter of the autoimmune antibody as well as the severity of the symptom</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with newly onset or chronic epilepsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with epilepsy according to the diagnostic criteria of International&#xD;
             League Against Epilepsy (ILAE) 2017&#xD;
&#xD;
          -  Age from 16 to 70 years old&#xD;
&#xD;
          -  The etiology of patients with epilepsy is unknown&#xD;
&#xD;
          -  The patient or guardian signs an informed consent and can cooperate with the&#xD;
             inspection and follow-up for six months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hereditary, infectious, and metabolic epilepsy&#xD;
&#xD;
          -  The investigation and follow-up cannot be completed due to vision, hearing, language&#xD;
             expression, disturbance of consciousness, and impaired understanding, and the guardian&#xD;
             cannot replace the completed&#xD;
&#xD;
          -  Patients with other progressive or systemic diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>autoimmune antibody</keyword>
  <keyword>diagnose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

